Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | The evolving myeloma diagnosis criteria

Faith Davies, Maria-Victoria Mateos and Shaji Kumar • 14 Sep 2019
IMW 2019
Multiple Myeloma Rare Diseases Smoldering Myeloma

Maria-Victoria Mateos, MD, PhD, from University Hospital of Salamanca, Salamanca, Spain; Faith Davies, MBBCh, MRCP, MD, FRCPath, from NYU Langone Medical Center, New York, NY, and Shaji Kumar, MD, from the Mayo Clinic, Rochester, Minnesota, discuss the changes in myeloma diagnosis criteria and the risk-stratification for smoldering myeloma. This interview took place at the International Myeloma Workshop (IMW) 2019, held in Boston, MA,

More from Faith Davies

2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
1:26
Identifying high-risk smoldering myeloma & minimizing treatment-related toxicity
Faith Davies • 26 Aug 2022
1:49
Factors to consider when sequencing therapies in myeloma
Faith Davies • 26 Aug 2022

More from Maria-Victoria Mateos

2:44
Dual-targeting bispecific antibody alnuctamab in R/R multiple myeloma
Maria-Victoria Mateos • 9 Dec 2023
2:26
Preliminary results of GEM2017FIT: comparing induction therapies in fit elderly patients with MM
Maria-Victoria Mateos • 9 Dec 2023
4:21
CAR-T in multiple myeloma: progress in the space and what can be done to improve patient outcomes
Maria-Victoria Mateos • 17 Feb 2024
Latest advances in T-cell engaging therapies for multiple myeloma
Adam Cohen et al. • 15 Apr 2023

More from Shaji Kumar

Evolution of risk stratification in SMM & MGUS: CTCs & imaging techniques
Bruno Paiva et al. • 25 Mar 2024
1:17
Novel treatment approaches being explored in amyloidosis: immunotherapeutic agents & venetoclax
Shaji Kumar • 11 May 2023
1:18
Overview of the updated NCCN Clinical Practice Guidelines for systemic AL amyloidosis
Shaji Kumar • 11 May 2023
1:26
Evaluating the efficacy of ixazomib, cyclophosphamide and dexamethasone in amyloidosis
Shaji Kumar • 11 May 2023

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals